Premium
Landmarks in non‐hormonal pharmacological therapies for castration‐resistant prostate cancer
Author(s) -
Clarke Noel W.
Publication year - 2012
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2012.11430.x
Subject(s) - cabazitaxel , docetaxel , medicine , prostate cancer , taxane , oncology , hormonal therapy , chemotherapy , androgen deprivation therapy , disease , cancer , breast cancer
• The treatment of metastatic and castration‐resistant prostate cancer (CRPC) has advanced considerably from the era where it was considered that the disease was resistant to chemotherapy. • Cytotoxic chemotherapy involving docetaxel is now used routinely as a first‐line therapy after failed first‐ and second‐line androgen deprivation in advanced disease, improving quality of life and to a limited extent, survival in patients with advanced prostate cancer. • The cytotoxic taxane, cabazitaxel has also become a second‐line treatment option for patients with CRPC failing previous docetaxel therapy. • Additionally, a broad range of agents are now available or under development including immune‐based therapies (cellular therapies and vaccines), bone‐targeting agents (anti‐osteolytic and anti‐tumour therapies) and molecular‐based agents targeting cellular control mechanisms. • Most of these remain experimental but on‐going pharmacological development will inevitably provide urologists and urological oncologists with a broader range of therapeutic options for better cancer management in the future.